Fresenius SE

Investor News 2009

03.11.2009Q1−3/2009: Strong organic sales growth achieved − Outlook for 2009 fully confirmed
(for additional tables please see pdf-file)
PDF Text as PDF-File
04.08.2009H1 2009: Maintains growth momentum; Confirms outlook
(for additional tables please see pdf-file)
PDF Text as PDF-File
03.06.2009Fresenius successfully raises € 138 million via a tap to its 2006 Senior Notes
PDF Text as PDF-File
03.06.2009Fresenius announces Senior Notes Offering
PDF Text as PDF-File
30.04.2009Q1 2009: Successful start into 2009
(for additional tables please see pdf-file)
PDF Text as PDF-File
23.04.2009Fresenius Biotech receives approval for Removab® by European Commission - First Drug worldwide for Treatment of Malignant Ascites
PDF Text as PDF-File
05.03.2009Fresenius SE joins the DAX 30
PDF Text as PDF-File
19.02.2009Successful 2008 − Financial targets fully met or exceeded − Positive outlook for 2009
PDF Text as PDF-File
18.02.2009EMEA-Committee for Medicinal Products for Human Use issues positive opinion for Removab® (catumaxomab) for the treatment of malignant ascites
PDF Text as PDF-File
15.01.2009Fresenius successfully raises US$ 800 million equivalent with Offering of Senior Notes
PDF Text as PDF-File
12.01.2009Fresenius announces Senior Notes Offering
PDF Text as PDF-File
Home  >  Investor Relations  >  News  >  Investor News  >  2009